MedTrace Logo

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

NCT06163170 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2024-04-18

No results posted yet for this study

Summary

The purpose of this study is to describe real-world safety outcomes in children with melanoma who are treated with nivolumab alone or nivolumab in combination with ipilimumab for unresectable or metastatic melanoma, or treated with adjuvant nivolumab after resection of stage IIB-IV melanoma. Demographic and clinical characteristics, and treatment patterns, will also be described in this population.

Conditions

Interventions

DRUG

Nivolumab +/- ipilimumab

Participants treated with nivolumab +/- ipilimumab for unresectable/metastatic melanoma

DRUG

Nivolumab

Participants treated with nivolumab as adjuvant therapy for resected stage IIB-IV melanoma

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-14
Primary Completion
2023-09-25
Completion
2023-11-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06163170 on ClinicalTrials.gov